



WORKSHOP
Purification Therapies
L'evoluzione della cura

27-28 Gennaio 2017

Milano
Centro Congressi Cariplo
Palazzo Confalonieri, Via Romagnosi 8



PROGRAMMA




Il danno da Ischemia Riperfusione


Giuseppe Castellano, M.D., Ph.D,
University of Bari

*Department of Emergency and Organ Transplantation
Nephrology, Dialysis and Transplant Unit*

Tissue injury in kidney Transplantation




Emerging Therapies Targeting Intra-Organ Inflammation in Transplantation




Consequences of donor organ ischemia on innate immune activation

PROCUREMENT


TRANSPLANT




Pattern recognition receptors expressed throughout the nephron



Inflammasome signaling in AKI



Maladaptive repair following acute kidney injury (AKI)



Deceased Donor Kidney Transplantation: A Model of Ischemia-Reperfusion Injury


Potential Deceased Donor
Hypotension, shock, acute
inflammation, kidney injury

Brain death or DCD


Ex vivo
Organ preservation –
Hypothermia and hypoxia

Recipient
Vascular anastomosis with
re-perfusion injury


Experimental strategies for identifying renoprotective approaches for AKI: from rodent to mammalian models.




Experimental strategies for identifying renoprotective approaches for AKI: from single to multiple models.




Role of complement in renal ischemia-reperfusion injury, inflammation, and progression to kidney fibrosis.



Multifaceted activity of the complement system in immunity.




Complement System 1/2




- Complement system: a biochemical cascade made up of approximately 30 serum and membrane-bound proteins
- The primary location for biosynthesis of complement is the liver.
- The extrahepatic complement synthesis contributes **approximately 10% of circulating C3**. The alternative sites for complement production include epithelial cells, fibroblasts, lymphocytes and macrophages derived from different organs, including the **kidney**.

Complement System 2/2



- Complement activation initiates a cascade reaction, which leads to the cleavage of inert plasmatic components that generate bioactive components, including C3b, C3a, C5a, and C5b-9, with pro-inflammatory, chemo-attractant, and cell-damaging functions.
- A set of at least seven proteins in plasma (C1 INH, C4b-binding protein, factor H, and factor I) or cell membranes (decay-accelerating factor, membrane cofactor protein, and CR1 (CD35)) modulate the complement proteins and protect host cells and tissues from complement damage.

Targeting the complement cascade: novel treatments coming down the pike




Joshua M. Thurman, Moglie Le Quintrec

Kidney International, Volume 90, Issue 4, 2016, 746–752

<http://dx.doi.org/10.1016/j.kint.2016.04.018>

The complement system and kidney disease



Joshua M. Thurman, Moglie Le Quintrec

Targeting the complement cascade: novel treatments coming down the pike

Kidney International, Volume 90, Issue 4, 2016, 746–752

The complement system and kidney disease

Afferent vesse|


- Inflow of complement proteins and fragments

Mesangium

- Mesangial immune-complexes
- Antibodies specific for antigens expressed in mesangial cells

Capillary wall

- Subendothelial immune-complexes
- Subepithelial immune-complexes
- Antibodies specific for antigens expressed in the GBM, podocytes, or mesangial cells.
- No intrinsic complement regulatory proteins expressed within GBM
- Loss of CR1 from podocytes



Efferent vesse|

- Concentrated complement proteins

Proximal tubule

- No complement regulators expressed on apical surface
- Local production of complement proteins
- Local production of ammonia
- Reduced complement regulators on basolateral surface after injury

Local Renal Synthesis of Complement



Interleukin 2 mediates stimulation of complement C3 biosynthesis in human proximal tubular epithelial cells.

[R.A. Brooimans](#), [A.P. Stegmann](#), [W.T. van Dorp](#), [A.A. van der Ark](#), [F.J. van der Woude](#), [L.A. van Es](#), and [M.R. Daha](#)

The first study to demonstrate that human renal proximal tubular epithelial cells synthesised and secreted complement component C3 in vitro was published by Brooimans et al. more than 20 years ago.



Complement C3 gene expression and regulation in human glomerular epithelial cells.

[S.H. Sacks](#), [W. Zhou](#), [A. Pani](#), [R.D. Campbell](#), and [J. Martin](#)

[Author information](#) ▶ [Copyright and License information](#) ▶

Resident renal cells, including tubular and glomerular epithelial cells, mesangial cells and endothelial cells can synthesise many, if not all complement proteins



Kidney International

Volume 51, Issue 3, March 1997, Pages 703-710



Laboratory Investigation

TNF- α regulation of C3 gene expression and protein biosynthesis in rat glomerular endothelial cells

[Neil S. Sheerin](#) , [Wuqing Zhou](#), [Stephen Adler](#), [Steven H. Sacks](#)

Transforming growth factor- β 1 regulates chemokine and complement production by human proximal tubular epithelial cells

[Jort S.J. Gerritsma](#), [Cees van Kooten](#), [Amout F. Gerritsen](#), [Leendert A. van Es](#), [Mohamed R. Daha](#)  

Intrarenal local complement synthesis is an important mediator in disease progression

Pediatric RESEARCH



Evidence of a Role for Local Complement Expression in a Murine Model of Progressive Glomerulonephritis

[Thomas R. Welch](#)^{1,3}, [Marie Frenzke](#)^{1,3} and [David Witte](#)^{2,4}

Local Synthesis of Complement System induces Acute Rejection (1)

ARTICLES

Local synthesis of complement component C3 regulates acute renal transplant rejection

JULIAN R. PRATT, SHAMIM A. BASHEER & STEVEN H. SACKS


*Department of Nephrology & Transplantation, King's College University of London,
Guy's Hospital, London, UK*

Correspondence should be addressed to S.H.S.; email: steven.sacks@kcl.ac.uk

NATURE MEDICINE • VOLUME 8 • NUMBER 6 • JUNE 2002

Local Synthesis of Complement System induces Acute Rejection (2)


Experimental Design:



Clinical use of Complement inhibitors

- 
- ✓ Currently, there are 2 FDA approved drugs aimed at inhibition of complement activation:
 - ✓ Eculizumab (anti-C5) which is approved for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
 - ✓ C1-Inhibitor (C1-INH), which is approved for use in patients with hereditary angioedema

C1 – INH as Complement system inhibitor in Kidney transplantation



One of the cardinal features of AMR is C4d (a fragment of C4 which remains on the target after C activation). C1-INH inactivates both C1r and C1s and is the only plasma protease that regulates the classic complement pathway thus preventing proteolytic activation of C4 and C2 that form C3 convertase

C1-INH can also inhibit the analogous serine proteases in the lectin pathway of C activation, as well as the alternative pathway through regulation of factor B binding to C3b as well as factor B cleavage by factor D

C1-INH also has major effects on activation of the coagulation cascade and on regulation of vascular permeability and inflammation by kinins

Complement in immune-mediated renal disease

1 Brain death /Cardiac Arrest

2 Ischemia/Reperfusion Injury

3 Lupus Nephritis

4 IgAN

4 aHUS

The pathophysiology of brain death

Brain Death

Cerebral injury and edema
Brain stem herniation



Immunological activation

Cytokine storm
Systemic inflammation
Complement activation



Tissue injury

Apoptosis/necrosis



Reduced organ viability

Allo-response
Delayed graft function

Brain death (BD) is complex and causes a **systemic** and **local inflammatory response** and resembles the systemic inflammatory response syndrome (**SIRS**).


The cause of this immune activation is not well understood.

Kidney from brain-dead organ donors give inferior results compared to kidneys from living donors:

Organ transplanted	1-year survival		5-year survival	
	2001–2002	2002–2003	1997–2002	1998–2003
Kidney				
Living donor	94.3%	94.6%	78.6%	79.2%
Deceased donor	88.7%	89.0%	65.7%	66.2%


Source: UNOS/OPTN.

The complement system in brain death




Local complement production by the kidney

Renal C3 expression in rats




Renal C3 expression in humans



Jeffrey Damman, et al. *Nephrol Dial Transplant*. 2011 Jul;26(7):2345-54.

Renal expression of complement in the donor graft




Components of the CP




Maarten Naesens, et al. *J Am Soc Nephrol*. 2009 Aug; 20(8):1839-51.

The role of C5a in brain-dead donors


Plasma C5a levels



Renal C5a-Receptor expression



The effect of renal C5a-C5aReceptor activation



Complement inhibition in brain-dead donors

Animal model:

Rat Brain death with Renal transplantation.

Intervention:





sCR1 = C3 inhibitor (soluble Complement Receptor 1)

Treatment:


- Before BD induction
- After BD induction

Conclusion:


Complement inhibition improves renal function after Tx in the recipient.



Ischemia/Reperfusion injury (IRI) in kidney transplantation





Renal Allograft	
Warm Ischemia Time (WIT) —time from extubation and cessation of circulation to removal of organ and perfusion with cold preservation solution	≤ 60 minutes
Cold Ischemia Time (CIT) —time from initiation of cold preservation solution to restoration of warm circulation after transplantation.	≤ 72 hours (≤24 hours ideal)



IRI is a frequent event in kidney transplantation, particularly when the kidney comes from a deceased donor, and can heavily influence both the early and the late function of a kidney allograft

The Lectin Pathway in IRI



•The recognition molecules of the MBL pathway include mannose binding lectins or ficolins.

These molecules bind to carbohydrate motifs displayed on the surface of bacteria, but MBL could bind neo-epitopes that are generated or exposed within the injured kidney (i.e Cytokeratin)

•Patients with high circulating concentrations of MBL have a poor outcome after renal transplantation.

Berger SP, AJP 2005

•Animal model

Transgenic mice deficient in both MBL-A and MBL- C, renal I/R injury


•Results

-Level of BUN and Creatinine showed that MBL double knock-out mice were protected by IRI, compared to WT mice.

-The protective phenotype was reversed following reconstitution of the mutant mice with recombinant MBL .

Swine model of IRI

Recombinant Human C1-INH
(Ruconest, Pharming, Leiden, The Netherlands)







Am J Pathol. 2010 Apr;176(4):1648-59. doi: 10.2353/ajpath.2010.090276. Epub 2010 Feb 11.


Therapeutic targeting of classical and lectin pathways of complement protects from ischemia-reperfusion-induced renal damage.

Castellano G¹, Melchiorre R, Loverre A, Ditunno P, Montinaro V, Rossini M, Divella C, Battaglia M, Lucarelli G, Annunziata G, Palazzo S, Selvaggi FP, Staffieri E, Crovace A, Daha MR, Mannesse M, van Wetering S, Paolo Schena F, Grandaliano G.





C1-INH inhibits C4d deposition








C4d deposits on renal Endothelial Cells



C1-INH treatment significantly reduced the numbers of inflammatory infiltrating cells




C1-INH infusion modulates NADPH activity and NOX-4 and NOX-2 expression




Complement-mediated endothelial dysfunction in I/R injury

In vivo


T24h ctr




T24h ctr





T24h C1-INH



T24h C1-INH





Endothelial to Mesenchymal Transition in AKI






Emerging role of Colec11 in IRI


IRI : Absence of CL-11 in *Colec11*^{-/-} mice permitted a less severe loss of renal function, with good preservation of renal architecture (Fig A, PAS staining) reduced leukocyte infiltration and tubular deposition of complement compared with that seen in *Colec11*^{+/+} mice




***Colec11*^{+/+} mice transplanted with kidneys from *Colec11*^{+/+} or *Colec11*^{-/-}: *Colec11*^{-/-} transplants showed strong protection from renal tubular damage compared with that observed in *Colec11*^{+/+} control transplants**



Role of Complement in renal IRI



Complement is bad for aging




- Augmented Wnt signaling is implicated in mammalian aging and aging-related phenotypes and fibrosis
- Serum C1q levels increase with aging
- The C1q complement protein is an activator of canonical Wnt signaling
- C1q-dependent Wnt signaling impairs the regenerative capacity of skeletal muscles


Complement C1q Activates Canonical Wnt Signaling and Promotes Aging-Related Phenotypes

Atsuhiko T. Naito, Tomokazu Sumida, Seitaro Nomura, Mei-Lan Liu, Tomoaki Higo, Akito Nakagawa, Katsuki Okada, Taku Sakai, Akihito Hashimoto, Yurina Hara, Ippei Shimizu, Weidong Zhu, Haruhiro Toko, Akemi Katada, Hiroshi Akazawa, Toru Oka, Jong-Kook Lee, Tohru Minamino, Toshio Nagai, Kenneth Walsh, Akira Kikuchi, Misako Matsumoto, Marina Botto, Ichiro Shiojima, and Issei Komuro*

RENAL GRAFT DETERIORATION




- Kidney transplantation is the best option for patients with ESKD;
- Despite improvements in first-year graft survival, long-term failure of kidney transplants remains an important clinical problem;
- There are several immunological and non-immunological factors related to renal graft deterioration, however several **histological lesions of chronic rejection and allograft nephropathy overlap** with those observed in **aging kidneys**



Braun H; J Am Soc Nephrol (2012),

Gekle, M., Kidney and aging— A narrative review, Exp. Gerontol. (2016)



CELLULAR SENESCENCE



‘Originally described in human fibroblasts by Hayflick and Moorhead,
‘ Cellular senescence’ describes a phenotype of permanent and irreversible growth arrest shown by mammalian cells.


Main mechanism are:

- Telomere shortening
- Cell cycle Inhibition



- A **telomere** is a region of repetitive nucleotide sequences at each end of a chromosome, which protects the end of the chromosome from degradation
- In humans, average telomere length declines from about 11kb at birth to less than 4 kb in old age
- In aging human kidney telomere shortening **is faster in cortex compared to medulla** (Melk A, JASN, 2000)

Senescence



Telomere Shortening and Cellular Senescence in a Model of Chronic Renal Allograft Rejection

S. A. Joosten, American Journal of Pathology, (2003)

Klotho: anti-aging gene

Nature. 1997 Nov 6;390(6655):45-51.

Mutation of the mouse klotho gene leads to a syndrome resembling ageing.


Kuro-o M¹, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, Ohyama Y, Kurabayashi M, Kaname T, Kume E, Iwasaki H, Iida A, Shiraki-Iida T, Nishikawa S, Nagai R, Nabeshima YI.



A defect in Klotho expression in mice leads to a premature-aging syndrome.

Overexpression of Klotho extends life span in mice (by 20 and 30%)

Klotho: anti-aging gene



M.G. Vervloet and T. E. Larsson, KI 2011




- ❖ α -Klotho is mainly expressed in renal tubular cells
- ❖ Membrane form regulates mineral homeostasis
- ❖ Soluble form, present in blood, urine and cerebrospinal fluid, acts as an endocrine factor interfering with renal and extrarenal functions

*Hu et al. Nephrol Dial Transplant 2012
Wang Y. Ageing Res Rev 2009*


Klotho modulation in IRI




Large White Pigs
(n=5 per group)




C1-INH treatment preserved renal Klotho



Ctr T24




C1-Inh T24







Klotho down-regulation in transplant recipients with DGF

Pre-Transplant




DGF



serum Klotho in DGF vs EGF patients at 2 years post-Transplant

CELLULAR SENESCENCE: Inflammaging



Post-operative stress,
inflammation, antibody
mediated Rejection,
Nephropathies, Diabetes


Inflammaging

CELLULAR SENESCENCE

- Telomere shortening
- Cell Cycle Inhibition


SASP
(Senescence-Associated Secretory Phenotype)
 increase IL-6, MCP-1, IL-1 β
 decrease EGF, IGF-1)

p16INK4a protein (gene CDKN2A) inhibits the activity of the cyclin-dependent kinases 4 and 6, leading to hypophosphorylation of the retinoblastoma gene and irreversible cell-cycle arrest



The tubular epithelial cells are most sensitive for the induction of senescence. [Joosten SA, KI 2004]

Figure 1 Innovative treatments at the donor, graft preservation or recipient levels to improve kidney recovery



Bon, D. *et al.* (2012) New strategies to optimize kidney recovery and preservation in transplantation
Nat. Rev. Nephrol. doi:10.1038/nrneph.2012.83

Adsorbimento: un possibile aiuto?

Controllando i livelli plasmatici di mediatori infiammatori, si potrebbero minimizzare i danni d'organo

IJAO

ISSN 0391-3988

Int J Artif Organs 2016; 00(00): 000-000

DOI: 10.5301/ijao.5000489

SHORT COMMUNICATION

First report of cytokine removal using CytoSorb® in severe noninfectious inflammatory syndrome after liver transplantation


Dana R. Tomescu^{1,2}, Simona Olimpia Dima³, Daniela Ungureanu⁴, Mihai Popescu², Dan Tulbure^{2,4}, Irinel Popescu^{2,3}

	GM-CSF	IFNg	IL-1b	IL-2	IL-4	IL-5	IL-6	IL-7	IL-8	IL-10	IL-12p70	IL-13	MCP-1	TNFa
T1	7,55	0,50	8,73	30,53	14,37	<2.00	223,18	51,31	210,69	188,95	14,43	19,22	1963,67	45,49
T2	7,55	<2.49	8,96	37,81	12,66	<2.00	89,99	52,20	297,74	113,74	12,95	19,22	2369,63	49,70
T3	7,20	<2.49	6,62	40,35	13,23	<2.00	75,65	51,31	53,22	17,54	14,18	18,84	257,07	35,13
T4	5,22	<2.49	2,39	22,27	14,37	<2.00	56,95	51,31	119,90	61,34	12,95	18,45	509,99	62,71
T5	6,19	6,80	7,79	22,43	21,25	12,94	31,81	51,31	299,89	48,65	13,68	18,84	399,14	64,65
Mean M	5,38	0,50	2,62	21,81	13,92	12,94	7,25	26,54	20,20	14,23	12,79	18,07	281,61	16,09

Rimozione delle citochine In Vivo


Hemoadsorption removes tumor necrosis factor, interleukin-6, and interleukin-10, reduces nuclear factor- κ B DNA binding, and improves short-term survival in lethal endotoxemia*

John A. Kellum, MD, FCCM; Mingchen Song, MD, PhD; Ramesh Venkataraman, MD



* Riduzione significativa di IL-6 e IL-10 ($p < .05$) in 8 h di emoperfusione con Cytosorb

Ridotta produzione di Citochine In Vivo




CytoSorb™ riduce sostanze, tra cui NF-κB, che determina la produzione di citochine.


Rimozione PAMPS & DAMPS In Vitro

In vitro adsorption of a broad spectrum of sepsis inflammatory mediators with CytoSorb® hemoadsorbent polymer beads


In Vitro Adsorption of DAMPS from Blood with CytoSorb® or Control Device



In Vitro Adsorption of Cytokines



In Vitro Adsorption of PAMPS from Blood with CytoSorb® or Control Device



Cytokines

- ✓ MIP1- α
- ✓ IL-6
- ✓ IL-8
- ✓ IFN- γ
- ✓ TNF- α

DAMPS

- ✓ Complement (C5a, C3a)
- ✓ S100 proteins (S100A8, S100A9)
- ✓ Procalcitonin
- ✓ HMG-B1

Metabolites

- ✓ Pancreatic Trypsin, Chymotrypsin
- ✓ Free hemoglobin, myoglobin
- ✓ Bilirubin

PAMPS

Bacterial Exotoxins:

- ✓
 - Pneumolysin, Streptolysin
 - SPE B
 - TSST-1
 - STX-1, STX-2
 - Panton-Valentine leukocidin
- ✓ Hemolysins:
 - *Staph aureus* α -toxin
- ✓ Mycotoxins
 - Aflatoxin



Table 1 Characteristics of current preservation solutions

Table 1 Characteristics of current preservation solutions							
Solution type	K ⁺ (mM)	Na ⁺ (mM)	Buffer (pH)	Impermeants	Adenosine (mM)	Antioxidants	Colloid
<i>Intracellular type solution [K⁺] >62 mM</i>							
Belzer UW [®] (ViaSpan™)	125	30	Phosphate (7.3)	+	5	+	HES (50 g/l)
<i>Intermediate type solution [K⁺] 7–62 mM</i>							
IGL-1 [®]	30	125	Phosphate (7.3)	+	5	+	PEG 35 kDa (1 g/l)
KPS-1 [®]	25	80	Phosphate HEPES (7.4)	+	5	+	HES (50 g/l)
Lifor™	16	98	Most commonly HEPES (7.1)	+	0.01	+	Dextran 70 and/or HES and/or other (45–55 g/l)
Celsior [®]	15	100	Histidine (7.3)	+	0	+	–
Polysol [®]	15	120	HEPES phosphate histidine (7.4)	+	5	+	PEG 35 kDa (20 g/l)
Custodiol [®] HTK	10	15	Histidine (7.2)	+	0	–	–
<i>Extracellular type solution [K⁺] <7 mM</i>							
SCOT15 [®]	5	118	Carbonate (7.4)	+	0	–	PEG 20 kDa (15 g/l)

Belzer UW[®] (Wisconsin Alumni Research Foundation, Madison, WI, USA); ViaSpan™ (DuPont Merck Pharmaceutical Company, Wilmington, DE, USA); IGL-1[®] (Institut Georges Lopez, Civrieux d'Azergues, France); KPS-1[®] (Lifeline Scientific, Itasca, IL, USA); Lifor™ (Lifeblood Medical, Freehold, NJ, USA); Celsior[®] (Genzyme Corporation, Cambridge, MA, USA); Polysol[®] (Doorzand Medical Innovations B.V., Amsterdam, The Netherlands); Custodiol[®] (Dr Franz Köhler Chemie GMBH, Alsbach-Hähnlein, Germany); SCOT15[®] (MaccoPharma, Tourcoing, France). Abbreviations: HEPES, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid; HES, hydroxyethyl starch; PEG, polyethylene glycol; UW, University of Wisconsin.


Bon, D. *et al.* (2012) New strategies to optimize kidney recovery and preservation in transplantation
Nat. Rev. Nephrol. doi:10.1038/nrneph.2012.83

Human Kidney




Decreased injury biomarkers with optimized normothermic perfusion

Urinary NGAL



Urinary KIM1



Acknowledgement



LEIDEN UNIVERSITY MEDICAL CENTER

Mohamed Daha
Cees van Kooten




university of
 groningen

Felix Poppelaar
Marc Seelen

PHARMING

Leiden, The Netherlands



Angelica Intini
Alessandra Stasi
Chiara Divella
Gigante Margherita
Pontrelli Paola
Rossana Franzin
Simona Simone
Marco Fiorentino
Vincenzo Montinaro
Giovanni B. Pertosa
Loreto Gesualdo

Giuseppe Lucarelli
Pasquale Ditunno
Michele Battaglia



Giovanni Stallone
Giuseppe Grandaliano





Thank you for your attention !